Crizotinib-induced immunogenic cell death in non-small cell lung cancer
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Immunogenic cell death (ICD) converts dying cancer cells into a therapeutic vaccine and stimulates antitumor immune responses. Here we unravel the results of an unbiased screen identifying high-dose (10 µM) crizotinib as an ICD-inducing tyrosine kinase inhibitor that has exceptional antineoplastic activity when combined with non-ICD inducing chemotherapeutics like cisplatin. The combination of cisplatin and high-dose crizotinib induces ICD in non-small cell lung carcinoma (NSCLC) cells and effectively controls the growth of distinct (transplantable, carcinogen- or oncogene induced) orthotopic NSCLC models. These anticancer effects are linked to increased T lymphocyte infiltration and are abolished by T cell depletion or interferon-γ neutralization. Crizotinib plus cisplatin leads to an increase in the expression of PD-1 and PD-L1 in tumors, coupled to a strong sensitization of NSCLC to immunotherapy with PD-1 antibodies. Hence, a sequential combination treatment consisting in conventional chemotherapy together with crizotinib, followed by immune checkpoint blockade may be active against NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“could be actioned therapeutically with PD-1-targeting mAb”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Liu et al., 2019
In the citing paper
“an effect that presumably reflected the ability of crizotinib to robustly drive ICD”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Liu et al., 2019
In the citing paper
“The multi-TKI crizotinib has also been associated with increased markers of T-cell exhaustion and PD-L1 upregulation on malignant cells in preclinical NSCLC models”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Liu et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Self-citationImmunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119 · cited 5×
“There is also evidence that cisplatin (CDDP), mitomycin C (MitoC) or other prominent chemotherapeutics are relatively inef fi cient due to their incapacity to stimulate ICD 7,17 .”
BackgroundInfluentialSelf-citation
Cited by
Immunogenic cell stress and death
Kroemer, G., Galassi, C., Zitvogel, L., & Galluzzi, L. (2022) · Nature Immunology · doi:10.1038/s41590-022-01132-2 · Cited by 1,353
Self-citationImmunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Martinez, A. B., Chan, T. A., Coukos, G., Demaria, S., Deutsch, E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000337 · Cited by 1,119
Detection of immunogenic cell death and its relevance for cancer therapy
Fucikova, J., Kepp, O., Kasikova, L., Petroni, G., Yamazaki, T., Liu, P., Zhao, L., Spisek, R., Kroemer, G., & Galluzzi, L. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03221-2 · Cited by 1,138
Self-citationKinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D., & Jänne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,024
Metadata
- Authors
- Liu, P., Zhao, L., Pol, J., Levesque, S., Petrazzuolo, A., Pfirschke, C., Engblom, C., Rickelt, S., Yamazaki, T., Iribarren, K., Senovilla, L., Bezu, L., Vacchelli, E., Sica, V., Melis, A., Martin, T., Xia, L., Yang, H., Li, Q., Chen, J., Durand, S., Aprahamian, F., Lefevre, D., Broutin, S., Paci, A., Bongers, A., Minard-Colin, V., Tartour, E., Zitvogel, L., Apetoh, L., Ma, Y., Pittet, M. J., Kepp, O., & Kroemer, G.
- Affiliations
- Université Paris-Sud (FR)
- Inserm (FR)
- Harvard University (US)
- Massachusetts Institute of Technology (US)
- Weill Cornell Medicine (US)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Institut Gustave Roussy (FR)
- Karolinska University Hospital (SE)
- Corresponding author
- Kepp, Oliver
- Kroemer, Guido
- ORCID
- Liu, Peng
- Zhao, Liwei
- Pol, Jonathan
- Petrazzuolo, Adriana
- Pfirschke, Christina
- Engblom, Camilla
- Rickelt, Steffen
- Yamazaki, Takahiro
- Iribarren, Kristina
- Senovilla, Laura
- Bezu, Lucillia
- Vacchelli, Erika
- Sica, Valentina
- Martin, Tiffany
- Xia, Lin
- Yang, Heng
- Li, Qingqing
- Chen, Jinfeng
- Durand, Sylvère
- Aprahamian, Fanny
- Broutin, Sophie
- Tartour, Eric
- Zitvogel, Laurence
- Ma, Yuting
- Kepp, Oliver
- Kroemer, Guido
- Venue
- Nature Communications
- Published
- 2019-04-02
- Volume
- 10
- Issue
- 1
- Pages
- 1486-1486
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC6445096
- OpenAlex
- W2930737113
- Cited by
- 302
- References
- 52
- Citations by year
- 2026: 23 · 2025: 33 · 2024: 40 · 2023: 53 · 2022: 49 · 2021: 50 · 2020: 37 · 2019: 17
- FWCI
- 16.07
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-04-17)
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- theses.fr (ABES) (submittedVersion)
- HAL (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Funders
- Association pour la Recherche sur le Cancer
- Seerave Foundation
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- E-Rare
- European Commission (HORIZON2020)
- Agence Nationale de la Recherche (E-Rare-2)
- Fondation Leducq
- Institut National de la Santé et de la Recherche Médicale
- National Natural Science Foundation of China (81671630, CAMS-I2M, 2017YFA0506200, 81722037)
- Fondation pour la Recherche Médicale (677251)
- Government of Jiangsu Province
- Ligue Contre le Cancer
- China Scholarship Council
- Natural Science Foundation of Jiangsu Province (BK20170006, BK20160379)
- Institut Universitaire de France
- Institut National Du Cancer
- Recruitment Program of Global Experts
- National Institutes of Health (2016-I2M-1-005, CA163109)
- Ludwig Center at Harvard
- National Key Research and Development Program of China (2017YFA0506200)
- Labex Immuno-Oncology
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine ((CAMS-I2M), 2016-I2M-1-005, CAMS-I2M, 2016-I2M-1-005)
- National Cancer Institute (U54CA163109)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- crizotinib, immunogenic cell death, non-small cell lung cancer, cisplatin, tyrosine kinase inhibitors, combination chemotherapy, T cell infiltration, PD-1, PD-L1, immune checkpoint blockade, antitumor immunity, interferon-gamma
- MeSH terms
- Crizotinib, Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Interferon-gamma, Lung Neoplasms, Mice, Inbred C57BL, T-Lymphocytes, Cell Death, Cell Line, Tumor, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Crizotinib-induced immunogenic cell death in non-small cell lung cancer. https://app.cochat.ai/papers/10.1038/s41467-019-09415-3
- The paper
- Liu, P., Zhao, L., Pol, J., Levesque, S., Petrazzuolo, A., Pfirschke, C., Engblom, C., Rickelt, S., Yamazaki, T., Iribarren, K., Senovilla, L., Bezu, L., Vacchelli, E., Sica, V., Melis, A., Martin, T., Xia, L., Yang, H., Li, Q., . . . Kroemer, G. (2019). Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nature Communications. https://doi.org/10.1038/s41467-019-09415-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.